Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Moshe C Ornstein

Showing results (51-60 of 61) with videos related to

Pageof 7
Sort By:
The Oncologist|June 23, 2025
Phase 1b/2 study of batiraxcept alone and in combination with cabozantinib with or without nivolumab for advanced clear cell renal cell carcinomaKathryn E Beckermann, Neil J Shah, Matthew T Campbell, et al.
The Oncologist|December 28, 2022
Avelumab Plus Axitinib as First-Line Therapy for Advanced Renal Cell Carcinoma: Long-Term Results from the JAVELIN Renal 100 Phase Ib TrialJames Larkin, Mototsugu Oya, Marcella Martignoni, et al.
Clinical Genitourinary Cancer|April 29, 2020
Myeloid-Derived Suppressor Cells in Nonmetastatic Urothelial Carcinoma of Bladder Is Associated With Pathologic Complete Response and Overall SurvivalJaleh Fallah, Claudia Marcela Diaz-Montero, Patricia Rayman, et al.
Urologic Oncology|December 9, 2019
Validation of a neuroendocrine-like classifier confirms poor outcomes in patients with bladder cancer treated with cisplatin-based neoadjuvant chemotherapyPetros Grivas, Tarek A Bismar, Aijai S Alva, et al.
Targeted Oncology|September 30, 2018
Immunological Correlates of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial CarcinomaAlice Tzeng, C Marcela Diaz-Montero, Patricia A Rayman, et al.
Targeted Oncology|March 25, 2020
Blood Myeloid-Derived Suppressor Cells Correlate with Neutrophil-to-Lymphocyte Ratio and Overall Survival in Metastatic Urothelial CarcinomaIris Y Sheng, Claudia Marcela Diaz-Montero, Patricia Rayman, et al.
Journal for Immunotherapy of Cancer|March 22, 2023
Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B)Michael B Atkins, Opeyemi A Jegede, Naomi B Haas, et al.
Urologic Oncology|April 3, 2018
Myeloid-derived suppressors cells (MDSC) correlate with clinicopathologic factors and pathologic complete response (pCR) in patients with urothelial carcinoma (UC) undergoing cystectomyMoshe C Ornstein, Claudia Marcela Diaz-Montero, Patricia Rayman, et al.
Journal for Immunotherapy of Cancer|October 17, 2022
Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor response in metastatic renal cell carcinomaLandon C Brown, Jason Zhu, Kunal Desai, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 18, 2018
Transcriptomic and Protein Analysis of Small-cell Bladder Cancer (SCBC) Identifies Prognostic Biomarkers and DLL3 as a Relevant Therapeutic TargetVadim S Koshkin, Jorge A Garcia, Jordan Reynolds, et al.
Pageof 7

Showing results (51-60 of 61) with videos related to

Sort By:
Pageof 7
The Oncologist|June 23, 2025
Phase 1b/2 study of batiraxcept alone and in combination with cabozantinib with or without nivolumab for advanced clear cell renal cell carcinomaKathryn E Beckermann, Neil J Shah, Matthew T Campbell, et al.
The Oncologist|December 28, 2022
Avelumab Plus Axitinib as First-Line Therapy for Advanced Renal Cell Carcinoma: Long-Term Results from the JAVELIN Renal 100 Phase Ib TrialJames Larkin, Mototsugu Oya, Marcella Martignoni, et al.
Clinical Genitourinary Cancer|April 29, 2020
Myeloid-Derived Suppressor Cells in Nonmetastatic Urothelial Carcinoma of Bladder Is Associated With Pathologic Complete Response and Overall SurvivalJaleh Fallah, Claudia Marcela Diaz-Montero, Patricia Rayman, et al.
Urologic Oncology|December 9, 2019
Validation of a neuroendocrine-like classifier confirms poor outcomes in patients with bladder cancer treated with cisplatin-based neoadjuvant chemotherapyPetros Grivas, Tarek A Bismar, Aijai S Alva, et al.
Targeted Oncology|September 30, 2018
Immunological Correlates of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial CarcinomaAlice Tzeng, C Marcela Diaz-Montero, Patricia A Rayman, et al.
Targeted Oncology|March 25, 2020
Blood Myeloid-Derived Suppressor Cells Correlate with Neutrophil-to-Lymphocyte Ratio and Overall Survival in Metastatic Urothelial CarcinomaIris Y Sheng, Claudia Marcela Diaz-Montero, Patricia Rayman, et al.
Journal for Immunotherapy of Cancer|March 22, 2023
Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B)Michael B Atkins, Opeyemi A Jegede, Naomi B Haas, et al.
Urologic Oncology|April 3, 2018
Myeloid-derived suppressors cells (MDSC) correlate with clinicopathologic factors and pathologic complete response (pCR) in patients with urothelial carcinoma (UC) undergoing cystectomyMoshe C Ornstein, Claudia Marcela Diaz-Montero, Patricia Rayman, et al.
Journal for Immunotherapy of Cancer|October 17, 2022
Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor response in metastatic renal cell carcinomaLandon C Brown, Jason Zhu, Kunal Desai, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 18, 2018
Transcriptomic and Protein Analysis of Small-cell Bladder Cancer (SCBC) Identifies Prognostic Biomarkers and DLL3 as a Relevant Therapeutic TargetVadim S Koshkin, Jorge A Garcia, Jordan Reynolds, et al.
Pageof 7